Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

被引:18
|
作者
Gil-Mohapel, Joana M. [1 ]
机构
[1] Univ Victoria, Div Med Sci, Isl Med Program, Victoria, BC V8W 2Y2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Apoptosis; Behavioral deficits; Excitotoxicity; Huntington's disease; Neuropathology; Therapy; YAC128 transgenic mice; TRANSGLUTAMINASE INHIBITOR CYSTAMINE; NEURONAL INTRANUCLEAR INCLUSIONS; RANDOMIZED CONTROLLED-TRIAL; FULL-LENGTH HUNTINGTIN; MOUSE MODEL; MUTANT HUNTINGTIN; TISSUE TRANSGLUTAMINASE; WILD-TYPE; CASPASE CLEAVAGE; STRIATAL NEURODEGENERATION;
D O I
10.1111/j.1755-5949.2011.00246.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an unstable expansion of cytosine-adenine-guanine (CAG) repeats in the HD gene. The symptoms include cognitive dysfunction and severe motor impairment with loss of voluntary movement coordination that is later replaced by bradykinesia and rigidity. The neuropathology is characterized by neuronal loss mainly in the striatum and cortex, and the appearance of neuronal intranuclear inclusions of mutant huntingtin. The mechanisms responsible for neurodegeneration are still not fully understood although excitotoxicity and a consequent increase in intracellular calcium concentration as well as the activation of caspases and calapins are known to play a key role. There is currently no satisfactory treatment or cure for this disease. The YAC128 transgenic mice express the full-length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. As such, these transgenic mice have been an invaluable model not only for the elucidation of the neurodegenerative pathways in HD, but also for the screening and development of new therapeutic approaches. Here, I will review the unique characteristics of this transgenic HD model and will provide a summary of the therapies that have been tested in these mice, namely: potentiation of the protective roles of wild-type huntingtin and mutant huntingtin aggregation, transglutaminase inhibition, inhibition of glutamate- and dopamine-induced toxicity, apoptosis inhibition, use of essential fatty acids, and the novel approach of intrabody gene therapy. The insights obtained from these and future studies will help identify potential candidates for clinical trials and will ultimately contribute to the discovery of a successful treatment for this devastating neurodegenerative disorder.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 50 条
  • [21] Huntington mutation produces age-dependent alterations in striatal excitation in YAC128 transgenic mice
    Bamford, N. S.
    Joyce, J. A.
    [J]. ANNALS OF NEUROLOGY, 2008, 64 : S115 - S115
  • [22] Mutant Allele Knockdown in the YAC128 Transgenic Mouse Model of Huntington's Disease Using an Artificial Transcription Factor
    Deng, P.
    Halmai, J. A. N. M.
    Sandoval, I. M.
    Manfredsson, F. P.
    Segal, D. J.
    Nolta, J. A.
    Fink, K. D.
    [J]. CELL TRANSPLANTATION, 2018, 27 (04) : 688 - 689
  • [23] Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice
    Brooks, Simon
    Higgs, Gemma
    Janghra, Nari
    Jones, Lesley
    Dunnett, Stephen B.
    [J]. BRAIN RESEARCH BULLETIN, 2012, 88 (2-3) : 113 - 120
  • [24] Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
    Garcia-Miralles, Marta
    Geva, Michal
    Tan, Jing Ying
    Yusof, Nur Amirah Binte Mohammad
    Cha, Yoonjeong
    Kusko, Rebecca
    Tan, Liang Juin
    Xu, Xiaohong
    Grossman, Iris
    Orbach, Aric
    Hayden, Michael R.
    Pouladi, Mahmoud A.
    [J]. JCI INSIGHT, 2017, 2 (23)
  • [25] Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease
    Van Raamsdonk, JM
    Pearson, J
    Bailey, CDC
    Rogers, DA
    Johnson, GVW
    Hayden, MR
    Leavitt, BR
    [J]. JOURNAL OF NEUROCHEMISTRY, 2005, 95 (01) : 210 - 220
  • [26] Automated deformation analysis in the YAC128 Huntington disease mouse model
    Lerch, Jason P.
    Carroll, Jeffrey B.
    Spring, Shoshana
    Bertram, Lisa N.
    Schwab, Claudia
    Hayden, Michael R.
    Henkelman, R. Mark
    [J]. NEUROIMAGE, 2008, 39 (01) : 32 - 39
  • [27] Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
    Slow, EJ
    van Raamsdonk, J
    Rogers, D
    Coleman, SH
    Graham, RK
    Deng, Y
    Oh, R
    Bissada, N
    Hossain, SM
    Yang, YZ
    Li, XJ
    Simpson, EM
    Gutekunst, CA
    Leavitt, BR
    Hayden, MR
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (13) : 1555 - 1567
  • [28] Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease
    Lerch, Jason P.
    Carroll, Jeffrey B.
    Dorr, Adrienne
    Spring, Shoshana
    Evans, Alan C.
    Hayden, Michael R.
    Sled, John G.
    Henkelman, R. Mark
    [J]. NEUROIMAGE, 2008, 41 (02) : 243 - 251
  • [29] Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington's Disease
    Nascimento-Castro, Cristine De Paula
    Winkelmann-Duarte, Elisa C.
    Mancini, Gianni
    Welter, Priscilla Gomes
    Placido, Evelini
    Farina, Marcelo
    Gil-Mohapel, Joana
    Rodrigues, Ana Lucia S.
    de Bem, Andreza Fabro
    Brocardo, Patricia S.
    [J]. BIOMEDICINES, 2022, 10 (06)
  • [30] Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease
    Van Raamsdonk, JM
    Pearson, J
    Slow, EJ
    Hossain, SM
    Leavitt, BR
    Hayden, MR
    [J]. JOURNAL OF NEUROSCIENCE, 2005, 25 (16): : 4169 - 4180